Table 1

Expression of activation markers, adhesion molecules and chemokine receptors in CD4+CD45RO+ Tck cells

Cell phenotype
Median MFI (range)/percentage positive (%) index
Changea
P
n






Day 0
Day 8




CD25
8.0 (2–49)/9%
61 (6–884)/18%
7.5
<0.0001
40
CD69
5.0 (2–43)/1.1%
41 (5–552)/26.7%
8
<0.0001
41
HLA-DR
19 (4–130)/9%
60 (11–238)/15%
3
0.0052
15
CD62L
22 (8–255)/17%
339 (7–1,040)/58%
15
<0.0001
31
CD18
107 (9–1,026)/97.5%
319 (53–2,040)/98.5%
3
0.0085
21
CD29
85 (6–668)/81%
152 (14–582)/97%
2
0.0132
35
CD49d
180 (5–634)/73.3%
465 (13–1,461)/82.3%
2.6
<0.0001
42
CCR7
12 (4–57)/7.4%
13 (3–138)/8.6%
1
NS
42
CXCR4
52 (18–494)/29%
270 (124–896)/86.4%
5
<0.0001
21
CXCR3
32.3 (9–309)/34.3%
40.4 (17–129)/34.0%
1
NS
21
CCR5
8.3 (4–28)/2%
10.7 (4–262)/6%
1
NS
21

Statistically significant differences in mean fluorescence intensity (MFI) between day 0 and day 8 values from different experiments were calculated using Wilcoxon rank test. aChange index is calculated with reference to Day 0. CCR, CC chemokine receptor; CXCR, CXC chemokine receptor; HLA, human leucocyte antigen; NS, not significant; Tck, cytokine-activated T.

Brennan et al. Arthritis Research & Therapy 2008 10:R36   doi:10.1186/ar2390